Targeting leukemia cells to improve treatment outcomes
Official title: Pharmacodynamically directed targeted therapy for leukemia
Funded at University of Cincinnati · NIH-11130087 · Data updated 2026-11-12
This study is looking for better ways to treat Acute Myeloid Leukemia (AML) by creating new drugs that can specifically attack leukemia cells and boost the immune system, which could help patients live longer and have better treatment results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | May 1, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2025 |
| Award (this year) | $683,472 |
| NIH project number | 1R01CA292084-01A1 |
| Project ID | NIH-11130087 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with Acute Myeloid Leukemia, particularly those with TP53 mutations.
✕Less likely to help
Patients with other types of leukemia or those who do not have Acute Myeloid Leukemia may not benefit from this research.
What this research studies
This research focuses on improving therapies for Acute Myeloid Leukemia (AML), a severe form of leukemia that often relapses despite treatment. The team aims to develop new drugs that specifically target leukemia cells while enhancing the immune response against them. By inhibiting a key enzyme involved in cell growth, the research seeks to differentiate leukemia cells from normal blood cells, potentially leading to better treatment outcomes. Patients may benefit from a combination of these new therapies with existing treatments to improve survival rates.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with Acute Myeloid Leukemia, potentially improving survival rates and reducing relapse.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in leukemia treatment, indicating potential for success with this novel approach.
Where this research is happening
-
University of Cincinnati
Cincinnati, United States Active
Researchers
- Principal investigator: Byrd, John C. — University of Cincinnati
- Study coordinator: Byrd, John C.
Related research
Other NIH-funded projects on the same topics.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Targeted therapy to reduce health disparities in pediatric leukemia
A pediatric leukemial therapy study focused on Hispanic/Latino children to improve outcomes by addressing genetic factors that make their leukemia harder to treat.
-
Bivalent CD47 Immunotoxin for Targeted Therapy of T-ALL in kids
A new targeted therapy using a two-part CD47-directed toxin is being studied for children with T-cell acute lymphoblastic leukemia who have limited treatment options.
-
New treatment to improve outcomes for Hispanic children with leukemia
This study is looking at how to improve treatment for Hispanic and Latino children with B-cell acute lymphoblastic leukemia (B-ALL), who often have a harder time responding to chemotherapy, by testing a new therapy that targets specific genetic factors to help them have better chances of recovery.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.